IQVIA's (IQV) "Equal Weight" Rating Reaffirmed at Barclays

Barclays restated their equal weight rating on shares of IQVIA (NYSE:IQV - Free Report) in a report issued on Thursday morning, MarketBeat reports. They currently have a $170.00 price objective on the medical research company's stock, down from their previous price objective of $235.00.

A number of other equities analysts have also recently commented on the company. Bank of America dropped their target price on IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a report on Friday, December 13th. Mizuho cut their price objective on shares of IQVIA from $242.00 to $210.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. Robert W. Baird decreased their price objective on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a research note on Tuesday, January 21st. Finally, StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Six investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, IQVIA currently has a consensus rating of "Moderate Buy" and an average price target of $241.50.

IQVIA Price Performance

Shares of NYSE:IQV traded down $1.73 during mid-day trading on Thursday, reaching $149.19. The stock had a trading volume of 475,645 shares, compared to its average volume of 1,663,360. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a market cap of $26.30 billion, a P/E ratio of 19.89, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. IQVIA has a 1 year low of $135.97 and a 1 year high of $252.88. The business's 50 day moving average price is $181.23 and its 200 day moving average price is $198.80.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts expect that IQVIA will post 10.84 EPS for the current fiscal year.

Institutional Trading of IQVIA

Institutional investors have recently made changes to their positions in the business. American National Bank & Trust acquired a new position in shares of IQVIA during the first quarter valued at about $26,000. Synergy Asset Management LLC purchased a new position in shares of IQVIA in the fourth quarter worth $33,000. ST Germain D J Co. Inc. lifted its stake in shares of IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares during the period. GKV Capital Management Co. Inc. purchased a new stake in shares of IQVIA during the fourth quarter valued at $39,000. Finally, Lee Danner & Bass Inc. purchased a new position in IQVIA in the 4th quarter worth $44,000. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.